Clinical trials: Schizophrenia Spectrum
Psychotic Disorder
Mobile After-Care Support App: Pilot RCT
The overall aim of this program of research is to refine and test the feasibility and acceptability of a newly developed mobile device-delivered app, called Mobile After-Care Support (MACS), to improve patients' coping and…
- Trial name
- MACS-RCT (NCT03955250)
- Testing
- Mobile After-Care Support (MACS) app, Mobile app attention control
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Butler Hospital
Schizophrenia, Schizoaffective Disorder
A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder
Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia.
- Trial name
- Switch Ext (NCT01143090)
- Testing
- Lurasidone HCl
- Where
- 27 sites in United States
- Volunteers
- 149 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Schizoaffective Disorder
Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder
The purpose of this study is to evaluate the use of the drug isradipine for cognitive enhancement in patients diagnosed with schizophrenia and schizoaffective disorder.
- Trial name
- NCT01658150
- Testing
- isradipine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Suicide, Psychosis
Cognitive Behavioral Suicide Prevention for Psychosis: Aim 2
Investigators will evaluate the feasibility and preliminary effectiveness of modified Cognitive Behavioral Suicide Prevention for psychosis (CBSPp) in comparison to services-as-usual (SAU) in a randomized controlled trial.
- Trial name
- NCT05345184
- Testing
- Cognitive Behavioral Suicide Prevention for psychosis (CBSPp), Services as Usual (SAU)
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- University of Michigan
Schizophrenia
A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia
The purpose of this study is to determine whether luvadaxistat is superior to placebo in improving cerebellar function as measured with the average percentage of conditioned responses during the eyeblink conditioning (EBC) test.
- Trial name
- NCT03359785
- Testing
- Luvadaxistat
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Neurocrine Biosciences
Psychotic Disorders, Bipolar Disorder
Supported Employment: Motivational Enhancement for Entry and Outcome
The purpose of this study is to compare 6 monthly counseling sessions to 6 monthly information sessions on Veterans' decisions to (a) participate in vocational rehabilitation services and (b) become employed.
- Conditions
- Psychotic Disorders, Bipolar Disorder, Unemployment
- Trial name
- NCT01041976
- Testing
- Adapted Motivational Interviewing (AMI), Support and Education for Recovery (SER)
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorder
Motivation Skills Training for Schizophrenia
This study will take place at one outpatient clinic serving adults with serious mental illness and will recruit ten individuals (N=10) with a DSM-5 diagnosis of schizophrenia or schizoaffective disorder to participate in an Open…
- Trial name
- MST (NCT05746455)
- Testing
- Motivation Skills Training (MST)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Columbia University
Schizophrenia
6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)
This is an extension study of A7501013 (P05771/NCT00145496) to further test the efficacy and safety of Asenapine compared with a marketed agent (olanzapine) in the treatment of patients with persistent negative symptoms of…
- Trial name
- NCT00174265
- Testing
- asenapine, olanzapine
- Volunteers
- 196 people
- Sponsor
- Organon and Co
Schizophrenia
A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
This study will evaluate weight gain of ALKS 3831 compared to olanzapine in adult subjects with schizophrenia.
- Trial name
- NCT02694328
- Testing
- ALKS 3831, Olanzapine
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 561 people
- Sponsor
- Alkermes, Inc.
Schizophrenia, Mental Disorder
Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole
The purpose of this study is to determine the usability of the Medical Information Device #1 (MIND1) system in adults with schizophrenia who are treated with oral aripiprazole.
- Conditions
- Schizophrenia, Mental Disorder, Nervous System Diseases
- Trial name
- NCT02219009
- Testing
- MIND1 System
- Where
- 6 sites in United States
- Volunteers
- 67 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)
A trial to compare if one 15 mg under the tongue tablet is equal to three 5 mg under the tongue tablets of Org 5222 (asenapine) in subjects with schizophrenia or schizoaffective disorder delivered.
- Trial name
- NCT01101464
- Testing
- Asenapine 3x5mg followed by 1x15mg, Asenapine 1x15mg followed by 3x5mg
- Volunteers
- 8 people
- Sponsor
- Organon and Co
Schizophrenia, Schizoaffective Disorder
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT05859698
- Testing
- Valbenazine
- Where
- 18 sites in United States
- Volunteers
- 59 people
- Sponsor
- Neurocrine Biosciences
Psychotic Disorders
Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics
This study will test the effectiveness of two different treatments for children and adolescents who have gained weight on their antipsychotic medications.
- Trial name
- IMPACT (NCT00806234)
- Testing
- Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Johns Hopkins University
MDD
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
To investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in active adults with MDD, 18 to 35 years old, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin…
- Trial name
- NCT02013609
- Testing
- Brexpiprazole
- Where
- 24 sites in United States
- Volunteers
- 48 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is safe and tolerable long term among clinically stable patients.
- Trial name
- NCT00641745
- Testing
- Lurasidone HCl, Risperidone
- Where
- 73 sites in United States, Argentina and 6 more
- Volunteers
- 629 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years
The purpose of this study is to evaluate the effectiveness and safety of paliperidone extended release (ER) in symptomatic participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment…
- Trial name
- NCT01362439
- Testing
- Paliperidone ER
- Volunteers
- 133 people
- Sponsor
- Janssen-Cilag S.p.A.
Paranoia, Schizophrenia
Oxytocin Treatment of Schizophrenia
Purpose: Test whether intranasal administration of the neuropeptide, oxytocin, improves social cognition, social functioning and decreases paranoia and other psychotic symptoms in schizophrenia.
- Conditions
- Paranoia, Schizophrenia, Schizoaffective Disorder
- Trial name
- OTS (NCT01028677)
- Testing
- intranasal spray with oxytocin, nasal spray without oxytocin
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Schizophreniform Disorder
Omega-3 Dietary Supplements in Schizophrenia
This 16-week placebo-control study looks to investigate whether patients with schizophrenia for two years or less may benefit from omega-3 supplements.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT01786239
- Testing
- Risperidone, Omega-3 capsules
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Delbert Robinson
Diabetes Mellitus, Bipolar Disorder
Improving Outcomes for Individuals With Serious Mental Illness and Diabetes
This project tests a model for improving illness self-management among persons who have both serious mental illness and diabetes and will be performed within a primary care setting at a safety net hospital system.
- Conditions
- Diabetes Mellitus, Bipolar Disorder, Depression, Psychotic Disorders
- Trial name
- TTIM (NCT01410357)
- Testing
- Targeted Training in Illness Management (TTIM)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Case Western Reserve University
Schizophrenia, Schizo Affective Disorder
The Efficacy of Neural Stimulation in Individuals With Schizophrenia
The purpose of this study is to understand the relationship between psychotic symptoms and social functioning in individuals with schizophrenia spectrum disorders.
- Trial name
- NCT05746494
- Testing
- tDCS
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The University of Texas at Dallas